JAC Advance Access originally published online on April 29, 2004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Antimicrobial Chemotherapy (2004) 53, 918-927
© 2004 The British Society for Antimicrobial Chemotherapy
Review |
Clinical efficacy of ketolides in the treatment of respiratory tract infections
Institute of Medical Microbiology, National Reference Centre for Streptococci, Pauwelsstrasse 30, 52074 Aachen, Germany
Ketolides are a new class of semi-synthetic agents derived from erythromycin A designed to overcome erythromycin A resistance in Streptococcus pneumoniae. Telithromycin (HMR 3647) is the first member of this new class to be approved for clinical use. Cethromycin (ABT-773) has been developed up to Phase III, but its further development seems questionable at the moment. Other ketolides are only in the first stages of preclinical development and may not be available within the foreseeable future. Ketolide compounds inhibit bacterial protein synthesis by interacting with the peptidyl transferase site of the 50S ribosomal subunit, and interact closely with domains II at A752 and V at A2058 and A2059 of the 23S rRNA. These compounds also inhibit the formation of the 50S subunit of the ribosome. Ketolides show good activity against the Gram-positive bacteria responsible for respiratory tract infections including penicillin G- and erythromycin A-resistant S. pneumoniae. The 15 clinical trials with telithromycin published to date include four randomized, double-blind comparative trials and three open-label studies in community-acquired pneumonia, three randomized double-blind trials in acute exacerbation of chronic bronchitis, two randomized double-blind trials in pharyngitis, and two double-blind comparative trials and one open-label trial in acute maxillary sinusitis. Clinical response rates were favourable in all clinical trials, with eradication rates in patients with pneumococcal bacteraemia and penicillin G- and erythromycin A-resistant pneumococcal infections at least as high as those of comparators. As resistance to macrolides continues to emerge, the availability of other ketolides besides telithromycin and a development programme for the application of ketolides in children would appear to be warranted to obtain a new class of antibiotics that may one day replace macrolides.
Keywords: respiratory tract infections, telithromycin, ABT-773, HMR 3647
* Tel: +49-241-80-89-787; Fax: +49-241-80-82-483; E-mail: reinert{at}rwth-aachen.de
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. van der Linden, A. Al-Lahham, S. Haupts, and R. R. Reinert Clonal Spread of mef-Positive Macrolide-Resistant Streptococcus pneumoniae Isolates Causing Invasive Disease in Adults in Germany Antimicrob. Agents Chemother., May 1, 2007; 51(5): 1830 - 1834. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. R. Reinert, M. R. Jacobs, P. C. Appelbaum, S. Bajaksouzian, S. Cordeiro, M. van der Linden, and A. Al-Lahham Relationship between the Original Multiply Resistant South African Isolates of Streptococcus pneumoniae from 1977 to 1978 and Contemporary International Resistant Clones J. Clin. Microbiol., December 1, 2005; 43(12): 6035 - 6041. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Faccone, P. Andres, M. Galas, M. Tokumoto, A. Rosato, and A. Corso Emergence of a Streptococcus pneumoniae Clinical Isolate Highly Resistant to Telithromycin and Fluoroquinolones J. Clin. Microbiol., November 1, 2005; 43(11): 5800 - 5803. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. R. Reinert, M. van der Linden, and A. Al-Lahham Molecular Characterization of the First Telithromycin-Resistant Streptococcus pneumoniae Isolate in Germany Antimicrob. Agents Chemother., August 1, 2005; 49(8): 3520 - 3522. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. R. Reinert, S. Reinert, M. van der Linden, M. Y. Cil, A. Al-Lahham, and P. Appelbaum Antimicrobial Susceptibility of Streptococcus pneumoniae in Eight European Countries from 2001 to 2003 Antimicrob. Agents Chemother., July 1, 2005; 49(7): 2903 - 2913. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. R. Reinert and A. Al-Lahham Time-Kill Study of the Activity of Telithromycin against Macrolide-Resistant Streptococcus pneumoniae Isolates with 23S rRNA Mutations and Changes in Ribosomal Proteins L4 and L22 Antimicrob. Agents Chemother., July 1, 2005; 49(7): 3011 - 3013. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. R. Reinert, A. Ringelstein, M. van der Linden, M. Y. Cil, A. Al-Lahham, and F.-J. Schmitz Molecular Epidemiology of Macrolide-Resistant Streptococcus pneumoniae Isolates in Europe J. Clin. Microbiol., March 1, 2005; 43(3): 1294 - 1300. [Abstract] [Full Text] [PDF]
|
|